Related Experiment Video

Updated: Aug 18, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Relationship between ZCE 025 blood clearance and liver accumulation in patients with colorectal cancer

J B Slater1, J M Slater, D S Gridley

  • 1Department of Radiology, Loma Linda University Medical Center, CA 92354, USA.

Immunopharmacology
|November 1, 1996
PubMed

Insights

Understanding monoclonal antibody (mAb) blood clearance is key for targeted radioisotope delivery. A 72-hour blood sample can predict mAb clearance and liver radiation dose, optimizing diagnostic and therapeutic applications.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Pharmacokinetics

Background:

  • Radiolabeled monoclonal antibodies (mAbs) show promise for targeted radioisotope delivery in diagnostics and therapeutics.
  • Optimizing mAb efficacy requires a deeper understanding of factors influencing their blood clearance kinetics.

Purpose of the Study:

  • To investigate factors affecting blood clearance of radiolabeled ZCE 025 mAb in colon cancer patients.
  • To determine the correlation between mAb blood clearance, liver radiation dose, and patient-specific parameters.

Main Methods:

  • Nine colon cancer patients received 111In-labeled ZCE 025 mAb.
  • Daily imaging (nuclear medicine, CT) and serial blood sampling over one week.
  • Calculation of mAb elimination half-life (t1/2 beta) and liver radiation dose.

Main Results:

  • Liver radiation dose directly correlated with the terminal half-life of the mAb in blood.
  • Patients' liver enzymes and physical parameters did not significantly impact liver uptake or mAb blood clearance.
  • Radioactivity levels in 48-h or 72-h blood samples correlated with both t1/2 beta and liver radiation dose.

Conclusions:

  • A single 72-hour blood sample can effectively predict both mAb elimination half-life and associated liver radiation dose.
  • This finding can help optimize dosing and patient selection for mAb-based therapies and diagnostics.

More Related Videos

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

Related Concept Videos

Clearance Models: Compartment Models01:25

Clearance Models: Compartment Models

Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume of...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...